Vitazi.ai and Eye Associates NM Team Up to Innovate Retinal Diagnosis with AI | Generative ai use cases in healthcare | Free ai tools for students | Examples of generative ai tools | Turtles AI

Vitazi.ai, a pioneer in ophthalmology, signs a strategic partnership with Eye Associates of New Mexico to improve early disease diagnosis through AI applied to retinal analysis. The agreement aims to develop advanced tools on OculoInsights™, Vitazi.ai’s innovative platform.

Key points:

• Innovative collaboration: Eye Associates of New Mexico will integrate AI into retinal diagnosis using Vitazi.ai’s technology.
• Advanced Oculomics: Analysis of the retina enables detection of systemic diseases before the onset of symptoms.
• OculoInsights™ AI platform: State-of-the-art tool for early detection of disease through retinal biomarkers.
• Long-term goal: Democratize access to early detection by improving preventive medicine.

Vitazi.ai, a leading ophthalmology company, has announced a collaboration with Eye Associates of New Mexico, the state’s largest ophthalmology network, to enhance the use of AI in retinal screening. With eleven clinics, three surgical centers, and ten optical outlets, Eye Associates services between 1,400 and 1,500 patients daily, making it a strategic partner in accelerating the adoption of new AI-based retinal screening technologies. This synergy represents a step forward in using the retina as a diagnostic window to identify systemic pathologies well in advance.

Oculomics is emerging as an important area of predictive medicine because of its ability to detect conditions such as cardiovascular disease, neurodegenerative disorders, and diabetes early, often before the onset of overt clinical symptoms. With this partnership, the team led by Vitazi.ai Chief Technology Officer Jeffrey Wigdahl, PhD, will initiate new research to develop advanced diagnostic tools within the proprietary OculoInsights™ platform. This web-based technology integrates AI models to provide physicians with sophisticated and reliable screening tools, making disease identification through retinal biomarkers more accessible and timely.

Vitazi.ai founder and CEO, Dr. Jeremy Stueven, MD, MBA, emphasizes how this collaboration is a key step toward a future in which early diagnosis through AI can significantly improve clinical outcomes. The company aims to create a technology ecosystem that can revolutionize preventive medicine by expanding the ability to detect disease early by building predictive models based on vast retinal datasets.

OculoInsights™ aims to make retinal analysis a commonly used diagnostic tool, providing specialists and healthcare professionals with innovative tools for the detection of diseases such as Alzheimer’s, hypertension, and metabolic disorders. Although current technology is not yet able to diagnose all of these conditions, the large pool of data made available by the collaboration with Eye Associates will enable Vitazi.ai to further refine its algorithms, aiming to improve screening tools and the overall level of health care.

With its ongoing commitment to innovation, Vitazi.ai is shaping the future of AI-based retinal screening, accelerating the path to increasingly predictive, accessible and effective medicine.